

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Europäisches Patentamt

(19) European Patent Office

Office européen des brevets

(11) Publication number:

0 283 055
B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of the patent specification:
29.08.90

(51) Int. Cl.: C07D 267/00, C07H 17/00,
A61K 31/395

(21) Application number: 88105626.1

(22) Date of filing: 08.04.88

(52) 10-Dihydro-10-deoxy-11-azaerythronolide-A-compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof.

(50) Priority: 03.09.87 YU 1631/87
18.01.88 YU 85/88

(73) Proprietor: SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka Industrija, n.s.o., Iv'e Lole Ribara 89, YU-41001 Zagreb(YU)

(43) Date of publication of application:
21.09.88 Bulletin 88/38

(72) Inventor: Djokic,Slobodan, Pantovcak 59,
YU-41000 Zagreb(YU)
Inventor: Lopotar,Nevenka, Sublinov breg 116,
YU-41000 Zagreb(YU)
Inventor: Kobrehel,Gabrijela, Trg Ivana Kukuljevica,
YU-41000 Zagreb(YU)
Inventor: Krnjevic,Hrvoje, Flajpanova 10,
YU-41000 Zagreb(YU)
Inventor: Carevic,Olga, Palmoticeva 7,
YU-41000 Zagreb(YU)

(45) Publication of the grant of the patent:
29.08.90 Bulletin 90/35

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(74) Representative: von Füner, Alexander, Dr. et al,
Patentanwälte v. Füner, Ebbinghaus, Finck
Mariahilfplatz 2 & 3, D-8000 München 90(DE)

(56) References cited:
JOURNAL OF THE CHEMICAL SOCIETY, Perkin Transactions I, no. 11, Nov 1986, London (GB);
S.DJOKIC et al.: "Erythromycin series. Part 11. Ring expansion of erythromycin A oxime by the Beckmann rearrangement"

EP 0 283 055 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description


The present invention relates to novel biologically active 10-dihydro-10-deoxo-11-azaerythronolide A compounds and their pharmaceutically acceptable acid addition salts, to methods and intermediates for the manufacture thereof and to their use in the manufacture of pharmaceuticals, especially anti-inflammatory agents.

It has been known that numerous antibiotics, in addition to their basic antibiotic activity, also exhibit antiinflammatory properties. This characteristic, however, is most often not exploited in the treatment of inflammatory processes that are not induced by pathogenous microorganisms in order to avoid the too rapid resistance of the microorganisms and the possible resulting oversensitivity of the human organism to them. Therefore there has been a need for substances with antiinflammatory activity and no simultaneous antibiotic properties. These are most often compounds, whose chemical structure is not similar to that of antibiotics or - exceptionally, they may be obtained from antibiotics by means of chemical transformations. Thus there has been known D-pencillamine derived from penicillin (Abraham et al., Nature, 151, 107 (1943) and Ruiz-Torres, Arzneimittel-Forsch., 24, 914 (1974).

In accordance with the known and assessed prior art, by means of the technique of Beckmann rearrangement of erythromycin A oxime followed by the reduction of the obtained erythromycin A imino ether, there was synthesized the 10-dihydro-10-deoxo-11-aza-erythromycin A (U.S. patent 4,328,334, 5/1982, Djokić et al.; J. Chem. Soc. Perkin Trans. 1, 1986, 1881). By the reductive methylation of the obtained amine in accordance with the modified Eschweiler-Clark process with formaldehyde in the presence of formic acid there was prepared the N-methyl-11-aza-10-deoxo-10-dihydroerythromycin A (GB patent 2,094,293 to Kobrehel and Djokić), a novel semisynthetic macrolide antibiotic of a 15-membered azalactone ring, which has been subjected to clinical tests under the generic name of azithromycin. The U.S. patent 4,464,527 (84) describes the process for obtaining the N-ethyl- and N-(n-propyl)-derivatives of 10-dihydro-10-deoxo-11-azaerythromycin A, which are also effective antibacterial agents.


The Applicant's own search of the prior art has revealed that 10-dihydro-10-deoxo-11-azaerythronolide A compounds and specifically their N-alkyl derivatives, their salts and/or O-and/or N,O-substituted alkanoyl derivatives have not been described as yet.

The first object of the present invention is a method for the manufacture of 10-dihydro-10-deoxo-11-azaerythronolide A compounds of the formula I




wherein R₁ stands for a hydrogen atom, a lower alkyl group, wherein the lower alkyl group comprises 1 to 3 carbon atoms, or a lower alkanoyl group, wherein the lower alkanoyl group comprises 1 to 3 carbon atoms, R₂, R₃, and R₄ have identical or different meanings and each stands for a hydrogen atom or a lower alkanoyl group, wherein the lower alkanoyl group comprises 1 to 3 carbon atoms, and optionally pharmaceutically acceptable acid addition salts thereof, which comprises

A) a one- or two-step hydrolysis of 10-dihydro-10-deoxo-11-alkyl-11-azaerythromycin A of the formula II



25 wherein R₁ has the above meanings, R₂ stands for a desosaminyl group, R₃ stands for a cladinosyl group and R₄ stands for a hydrogen atom, or
B) the reaction of 10-dihydro-10-deoxo-11-azaerythronolide A of the formula III



50 with aliphatic aldehydes of the formula


R₅-CHO (IV)

55 wherein R₅ stands for hydrogen or a lower alkyl group, namely a C₁₋₃ alkyl group,
in the presence of formic acid or hydrogen in the presence of a noble metal catalyst, and
C) optionally subjecting the products obtained according to A) or B) to acylation with lower aliphatic ac-
id anhydrides, namely C₁₋₃ aliphatic acid anhydrides,
and optionally converting the products obtained according to A), B) or C) into pharmaceutically accept-
able acid addition salts.

60 The hydrolysis according to the variant A) of the present inventive method is performed in a single or
in two steps. In the single-step embodiment the hydrolysis is achieved by means of highly concentrated
inorganic acids in the presence of an inert solvent, e.g. chloroform, by means of heating under a reflux
condenser for 16 to 60 hours, followed by the isolation of the product by means of extraction with the
same solvent at a pH of 8 to 9.
65

The two-step hydrolysis comprises

- 5 i) the hydrolysis of the compound of the formula (II) with diluted inorganic acids at room temperature for 10 to 20 hours and the extraction of the obtained intermediate 6-O-desosaminy-10-dihydro-10-deoxy-
11-alkyl-11-azaerythromycin A of the formula V



30 wherein R₁ and R₂ have the above-defined meanings, in a non-solvent, such as methylene chloride, chloroform or diethyl ether, at a pH of 9 to 11, and

- ii) the subsequent subjecting of the isolated intermediate (V) to hydrolysis as described above for the one-step method.

35 The method B) of the present invention comprising the reductive alkylation of the compound (III) may be performed either

- B₁) with formaldehyde in the presence of formic acid in an inert solvent, or
B₂) with aldehydes of the formula (IV) in the presence of hydrogen and a noble metal catalyst in an inert solvent.


40 According to the method B₁) of the present invention the compound (III) is reacted with a 1-3 equimolar excess of formaldehyde in the presence of at least the identical quantity of formic acid, in an inert solvent, such as acetone, halogenated hydrocarbons, preferably chloroform, at reflux temperature of the reaction mixture for 2 to 8 hours, yielding the compound of the formula (I), wherein R₁ stands for a methyl group and R₂, R₃ and R₄ stand each for a hydrogen atom.

45 The method B₂) comprises the reductive alkylation of the compound (III) with aldehydes of the formula (IV) with hydrogen in the presence of noble metal catalysts in the inert solvent, e.g. a lower alcohol such as methanol or ethanol (96% mass/mass). In practice, the reaction is performed with a 1-2 fold equimolar excess of the aldehyde and a 0.5 to equimolar quantity of the noble metal catalyst, preferably Pd/C (palladium-on-charcoal) (5% mass/mass). The reductive alkylation is performed at moderate temperature, e.g. 18 to 25°C, in a hydrogen atmosphere at the starting pressure of 10 to 30 bar for 2 to 10 hours.

50 After the completed reaction the catalyst is filtered off and the product is isolated in a conventional manner, most suitably by the evaporation of the alcohol at reduced pressure and the isolation of the obtained product of the formula (I), wherein R₁ stands for a lower alkyl, wherein the lower alkyl group comprises 1 to 3 carbon atoms, and R₂, R₃ and R₄ stand each for a hydrogen atom, by means of extracting the aqueous suspension with an inert organic solvent such as methylene chloride, chloroform or carbon tetrachloride.

55 The acylation may be performed by standard acylation methods (e.g. Jones et al, J. Med. Chem. 15, 631 (1972)).

60 A further object of the present invention are novel 10-dihydro-10-deoxy-11-azaerythronolide A compounds of the formula (IA)



wherein R_1' stands for R_1 with the exception of a hydrogen atom and R_2 , R_3 and R_4 have the above defined meanings, and pharmaceutically acceptable acid addition salts thereof.

25 The intermediates of the formula (V) are also novel compounds and constitute a further object of the present invention.

It should be noted that the compound of the formula (I), wherein R_1 stands for a hydrogen atom, *per se* pertains to the state of the art (see the afore-cited S. Djokić et al, J. Chem. Soc., Perkin Trans 1, 1986, 1881); the Patentee's have, however, discovered a new, much improved method of the manufacture thereof according to the above-defined process A) as well as its medicinal use, which has not been known as yet. The pharmaceutically acceptable acid addition salts of 10-dihydro-10-deoxy-11-azaerythronolide A compounds (I), which are also encompassed by the present invention, are obtained by the reaction of 10-dihydro-10-deoxy-11-azaerythronolide A compounds (I) with an at least equimolar quantity of a suitable acid, e.g. hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, propionic, citric, succinic, benzoic acids etc., optionally in the presence of a solvent inert at the reaction conditions. The acid addition salts are isolated by filtration, provided they are not soluble in the applied inert solvent, or by means of precipitation achieved by the addition of a non-solvent for the corresponding salt, or by the evaporation of the solvent, most often by lyophilization.

40 Further objects of the present invention are pharmaceutical compositions comprising an effective amount of the compounds of the formula (I) as well as of their pharmaceutically acceptable acid addition salts, methods for treating human and animal inflammatory diseases and methods for the manufacture of pharmaceuticals comprising a compound of the formula (I).

45 It has been found by *in vitro* and *in vivo* investigations that the compounds of said formula (I) exhibit a strong antiinflammatory activity. Their antiinflammatory properties were examined *in vitro* in comparison with diclofenac (DICL) and D-penicillamine (D-PEN), which are known antiinflammatory agents, on the model of extracellular release of lysosomal enzymes by human polymorphonucleic leukocytes (Weissman et al, J. Exp. Med., 134, 149 (1971); Carević, Agents and Actions 16, 407 (1985)) and the results are presented in the enclosed Diagrams 1 and 2.

50 It is evident from the Diagram 1 that the hydrolysis of azithromycin and the preparation of the corresponding 6-O-desosaminyl derivative (DESAZ) yields a product of a good antiinflammatory activity. In the concentration of 10^{-5} DESAZ shows an approximately equal activity as D-PEN in the concentration of 10^{-7} . By the elimination of both sugar groups and by the synthesis of 10-dihydro-10-deoxy-11-methyl-11-azaerythronolide A (AZER) there is obtained a compound which strongly inhibits the extracellular release of lysosomal enzymes from polymorphonucleic leukocytes with a similar activity as D-PEN or - in a concentration of 10^{-7} - with a stronger one.

55 In *in vitro* experiments DICL does not influence the extracellular release of enzymes. The *in vitro* activity of N-ethyl-(AE) or N-(n-propyl) derivatives is somewhat lower in comparison with AZER (Diagram 2). Yet the acylation of AZER with the acetic acid anhydride and the preparation of 4,6,13-triacetyl-10-dihydro-10-deoxy-11-methyl-11-azaerythronolide A (ALA-3) does not result in a substantial change in the *in vitro* activity.

60 There were also performed *in vivo* investigations on a model of an adjuvant-induced arthritis in rats (Perason et al, Arthritis Rheum., 2, 440 (1959); Carević, Publ. Yug. Acad. of Sci., 7, 415 (1985)). It can be concluded from the Diagram 3 that AZER significantly reduces the extracellular release of lysosomal enzymes into the synovial fluid of rats with the adjuvant-induced arthritis and that it exhibits a level of

activity, which is equal to that of D-PEN and significantly higher than that of DICL. DESAZ showed a somewhat lower activity than D-PEN and DICL.

It is evident from the above results that the *in vivo* method is comparable with the *in vitro* assays. In these experiments the *in vitro* and *in vivo* investigated substances did not significantly influence the release of the enzyme lactate dehydrogenase (A), which proved that the cellular membrane was not significantly affected.

The antiinflammatory activity was also measured on the carageenin-induced oedema of the rat's paw (Crunkhorn et al, Br. J. Pharm., 42, 392 (1971)).

The obtained results (30-40 %) of the compounds (I) did not significantly exceed those of D-PEN and Acisal (35-45 %). The activity of N-ethyl- and N-(n-propyl) derivatives (I) is on the level of the antiinflammatory activity of AZER. The O-and/or N,O-substituted compounds (I) and their salts, however, exhibited an improved activity in comparison with D-PEN.

The invention is illustrated by the following Examples.

15 Example 1

10-dihydro-10-deoxo-11-azaerythronolide A

A mixture of 10-dihydro-10-deoxo-11-azaerythromycin A (100 g, 136.06 mmole), 6 M HCl (750 ml) and CHCl₃ (380 ml) was kept at the boil under a reflux cooler for 16 hours. After cooling to ambient temperature the layers were separated and the aqueous layer was extracted by chloroform (2 × 100 ml). By the addition of sodium lye the pH of the aqueous solution was adjusted to 5.0 and it was re-extracted by means of chloroform (3 × 100 ml). The same procedure was repeated at a pH of 8.5 (3 × 250 ml). The chloroform extracts of a pH 8.5 were dried over K₂CO₃ and evaporated at reduced pressure, yielding 53.77 g (94.2 %) of the crude 10-dihydro-10-deoxo-11-azaerythronolide A. After the crystallization from diethyl ether (300 ml) there were obtained 34.45 g of the homogeneous product (TLC, C₆H₆:CHCl₃:CH₃OH 40:55:5, NH₃ R_f 0.233) of the physical-chemical constants as described in J. Chem. Soc., Perkin Trans. 1, 1986, 1881.

30 Example 2

10-dihydro-10-deoxo-11-methyl-11-azaerythronolide A

A mixture of azithromycin (II) (10 g, 13.35 mmole), 6 M HCl (75 ml) and chloroform (38 ml) was kept at the boil under a reflux cooler for 48 hours. After cooling to ambient temperature the layers were separated and the aqueous layer was extracted with chloroform. The aqueous solution was adjusted to a pH of 5.0 by means of sodium lye and extracted again by means of chloroform. The same procedure was repeated at a pH of 8.5. The chloroform extracts were obtained at a pH of 8.5 and were concentrated *in vacuo* to a volume of about 10 ml and left standing to crystallize. After the filtration and drying there were obtained 4.7 g (81.2 %) of the product, which was optionally recrystallized from chloroform. M.p. 208-210°C.

		C	H	N
45	C ₂₂ H ₄₃ NO ₇ :	calc.	60.94	10.00
		found	60.72	9.63
				3.23
				2.96

Example 3

50 6-O-desosaminyl-10-dihydro-10-deoxo-11-methyl-11-azaerythromycin A

A solution of azithromycin (10 g, 13.35 mmole) in 0.25 M HCl (500 ml) was kept standing for 15 hours at ambient temperature. After the extraction with chloroform (3 × 75 ml) the extracts were washed with 1 M HCl and water. The combined aqueous layer was alkalized to a pH value of 10 by means of sodium lye and re-extracted by means of chloroform. The chloroform extracts were dried over K₂CO₃ and subsequently evaporated to dryness under reduced pressure. After the washing of the crude product with ether, there were obtained 6.9 g (87.8 % theor.) of the product. M.p. 203-205°C.

		C	H	N
60	C ₃₀ H ₅₈ N ₂ O ₉ :	calc.	60.99	9.90
		found	60.63	9.58
				2.96
				4.36

Example 4

In accordance with the process described in Example 1, from 10 g of the product of Example 3 there were obtained 6.56 g (89.4 %) of the product of Example 2.

5

Example 5

10-dihydro-10-deoxo-11-methyl-11-azaerythronolide A

10 Into a solution of 10-dihydro-10-deoxo-11-azaerythronolide A (1 g, 2.38 mmole) in CHCl_3 (20 ml) there were charged 0.184 ml (2.38 mmole) of formaldehyde (36 %) and 0.183 ml (4.77 mmole) of formic acid (98-100 %) and the reaction mixture was refluxed under stirring for 8 hours. Then it was cooled to ambient temperature and left standing for 24 hours, whereupon the precipitated crystals were filtered off, washed with chloroform and dried, yielding 1.0 g (96.5 %) of the crude 10-dihydro-10-deoxo-11-methyl-11-azaerythronolide A. The product was optionally crystallized from chloroform (TLC, R_f 0.306).
M.p. 208-210°C
 $^1\text{H NMR}$ (CD_3OD): 2.351 ppm ($\text{N}-\text{CH}_3$).

20

Example 6

10-dihydro-10-deoxo-11-ethyl-11-azaerythronolide A

25 In a solution of 10-dihydro-10-deoxo-11-azaerythronolide A (5 g, 11.92 mmole) in ethanol (96 %) (50 ml) there were charged acetaldehyde (7 ml, 120.5 mmole) and palladium-on-charcoal (5 %) (2.5 g), whereupon the reaction mixture was hydrogenated under stirring for 10 hours at 20 bar. The catalyst was filtered off, washed with ethanol (20 ml) and the combined liquid phase was concentrated by evaporation at reduced pressure to a volume of about 30 ml. To the reaction mixture there were added water (100 ml) and CHCl_3 (50 ml), the pH was adjusted to 4.5 by the addition of 2 M HCl, the layers were separated and the aqueous phase was re-extracted with chloroform (2 x 50 ml). The reaction step of extraction with chloroform was repeated after the alkalization to a pH value of 8.5 with an aqueous solution of sodium lye (3 x 50 ml), the combined chloroform extracts were dried over K_2CO_3 and evaporated at reduced pressure, yielding 4.65 g (87.2 %) of the crude 10-dihydro-10-deoxo-11-ethyl-11-azaerythronolide A. The obtained product was suspended in diethylether (10 ml), stirred for 1 hour at ambient temperature, filtered, the precipitate was washed with diethyl ether and dried, yielding 3.2 g of the chromatographically homogeneous product (TLC, R_f 0.390), m.p. 204-208°C.

35

Example 7

10-dihydro-10-deoxo-11-(n-propyl)-11-azaerythronolide A

40

40 Into a solution of 10-dihydro-10-deoxo-11-azaerythronolide A (6 g, 14.30 mmole) in ethanol (96 %) (60 ml) there were charged propionaldehyde (11.4 ml, 157.31 mmole) and palladium-on-charcoal (5 %) (3.0 g), whereupon the reaction mixture was hydrogenated under stirring for 10 hours at 22 bar. The catalyst was filtered off, the filtrate was concentrated by evaporation at reduced pressure into a thick syrup, whereupon the product was isolated by pH-gradient extraction. Into the reaction mixture there were added water (100 ml) and dichloro methane (50 ml), the pH was adjusted to 4.5 with 2 M HCl, the layers were separated and the aqueous layer was re-extracted with dichloro methane (2 x 50 ml). After the alkalization by means of an aqueous solution of sodium lye, the reaction step of extraction with dichloro methane was repeated at a pH of 8.5 (1 x 150 ml, 2 x 50 ml). The combined organic extracts at a pH of 8.5 were filtered, the filtrate was concentrated by evaporation at reduced pressure into a thick suspension, the separated crystals were filtered off, washed with dichloro methane and dried to obtain the chromatographically homogeneous title product (TLC, R_f 0.415). Yield 4.3 g (65.2 %). M.p. 212-216°C.

55

Example 8

4-O-acetyl-10-dihydro-10-deoxo-11-methyl-11-azaerythronolide A

60

60 Into a solution of 10-dihydro-10-deoxo-11-methyl-11-azaerythronolide A (5 g, 1.53 mmole) in pyridine (30 ml) there was added acetic anhydride (30 ml) and the reaction mixture was left standing for 2 hours at ambient temperature. The acylation step was stopped by the addition of ice and the product was isolated by the extraction with chloroform at a pH of 9.0 (3 x 50 ml). The combined organic extracts were dried over K_2CO_3 and evaporated, yielding 3.4 g of the crude product. The suspending of the precipitate in diethyl ether (10 ml), the stirring of the suspension for 1 hour at ambient temperature and the filtration yielded 1.75 g (53.2 %) of the title product, m.p. 187-189°C (TLC, R_f 0.564).

65

IR(KBr): 1725 (C=O lactone and ester) and 1235 cm⁻¹ (OAc)
 1H NMR (CD₃OD): 2.343 (s, 3H, N-CH₃), 2.052 (s, 3H, 4-OAc) and 5.227 ppm (d, 1H, 4-H).

5 By means of the same process, with the exception that acetanhydride was substituted by propionic acid anhydride, there was prepared the corresponding 4-O-propionyl derivative.

Example 9

10 4,6,13-O-triacetyl-10-dihydro-10-deoxo-11-methyl-11-azaerythonolide A

15 Into a solution of 10-dihydro-10-deoxo-11-methyl-11-azaerythonolide A (5 g, 11.53 mmole) in pyridine (50 ml) there was charged acetanhydride (50 ml) and the reaction mixture was left standing for 7 days at ambient temperature. The reaction was stopped by the addition of ice and the product was isolated by means of extraction with chloroform as described in Example 8. The combined organic extracts were dried over K₂CO₃, evaporated to dryness and chromatographed on a silica gel column by means of the system CH₂Cl₂/CH₃OH/NH₄OH 90:9:1.5. The combining of the fractions of the less mobile substance, the evaporation of the solvent and the drying of the obtained amorphous product yielded the 4,6,13-O-triacetyl derivative, m.p. 180-182°C (R_f 0.337).

20 IR(KBr): 1740 (C=O, ester), 1715 (C=O, lactone) and 1240 cm⁻¹ (OAc)

25 ¹³C NMR (CDCl₃): 43.1 (q, N-CH₃), 173.5 (s, C=O lactone) and 170.2, 170.1 and 169.1 ppm (s, C=O acetates).

Example 10

25 11-N,4,6-O-triacetyl-10-dihydro-10-deoxo-11-azaerythonolide A

30 From 10-dihydro-10-deoxo-11-azaerythonolide A (5.0 g, 11.9 mmole) and acetanhydride (50 ml) in pyridine (50 ml) there was obtained by acetylation according to the process described in Example 8 the crude 11-N,4,6-O-triacetyl-10-dihydro-10-deoxo-11-azaerythonolide A. The acetylation reaction was stopped after 24 hours, the product was isolated by means of conventional methods of extraction with chloroform and the obtained crude precipitate was purified by means of suspension in diethyl ether (50 ml), the stirring of the reaction suspension during 1 hour at ambient temperature and the filtration of the insoluble title product. The yield: 4.08 g (68.3 %).

35 M.p. 220-223°C

R_f 0.417

IR(KBr): 1715 (C=O, lactone and ester), 1605 (N-CH₃) and 1240 cm⁻¹ (OAc).

40 1H NMR (CD₃OD): 2.115 (s, 3H, N-CH₃), 2.053 (s, 3H, 4-OAc) and 2.040 ppm (s, 3H, 6-OAc).

Example 11

45 10-dihydro-10-deoxo-11-methyl-11-azaerythonolide A hydrochloride

50 10-dihydro-10-deoxo-11-methyl-11-azaerythonolide A (4.34 g, 10 mmole) was suspended in 25 ml of water, and under stirring, by the dropwise addition of 0.25 N HCl during 1 hour, the pH was adjusted to 5.8. The clear reaction mixture was stirred for an additional hour at ambient temperature, filtered and lyophilized; yield 4.48 g (95.5 %) of 10-dihydro-10-deoxo-11-methyl-11-azaerythonolide A hydrochloride.

55 1H NMR (CD₃OD): 3.03 ppm (s, 3H, N-CH₃)

Analysis:	Cl
calc.	7.54%
found	6.97%

60 In an analogous manner, by the substitution of hydrochloric acid with hydrobromic, acetic, sulfuric, phosphoric, citric, benzoic etc. acids, there were prepared the corresponding salts of 10-dihydro-10-deoxo-11-alkyl-11-azaerythonolide A and N- and/or N,O- substituted derivatives thereof.

Example 12

10-dihydro-10-deoxo-11-methyl-11-azaerythronolide A (method B)

5 According to the process of Example 5, starting from 10-dihydro-10-deoxo-11-azaerythronolide A (1 g, 2.38 mmole), formaldehyde (36 %) (0.184 ml, 2.38 mmole) and formic acid (98-100 %) (0.183 ml, 4.77 mmole) and reacting in acetone (20 ml), there were obtained 0.93 g (89.8 %) of the title product.

Example 13

10 10-dihydro-10-deoxo-11-ethyl-11-azaerythronolide A (method B)

According to the process as described in Example 1, starting from 10-dihydro-10-deoxo-11-ethyl-11-azaerythromycin A (5 g, 6.55 mmole) there were isolated 2.45 g (83.57 %) of the title product with the same physical-chemical constants as described in Example 6.

15

Example 14

10-dihydro-10-deoxo-11-(n-propyl)-11-azaerythronolide A (method B)

20 According to the process as described in Example 1, starting from 10-dihydro-10-deoxo-11-(n-propyl)-11-azaerythromycin A (5 g, 6.44 mmole) there were isolated 2.4 g (80.7 %) of the title product of the same physical-chemical constants as described in Example 7.

Example 15

25

6-O-desosaminyl-10-dihydro-10-deoxo-11-ethyl-11-azaerythromycin A

30

10-dihydro-10-deoxo-11-ethyl-11-azaerythromycin A (1 g, 1.31 mmole) was dissolved in 0.25 M HCl (50 ml) and left standing for 16 hours at ambient temperature. The reaction mixture was then extracted with chloroform (3×10 ml) and the combined organic extracts were washed with 1 M HCl and water. The combined aqueous layer was alkalized with an aqueous solution of sodium lye to a pH of 10 and re-extracted with chloroform (3×20 ml). The chloroform extracts were dried over K_2CO_3 and evaporated to dryness. After washing the crude product with ether there were obtained 0.7 g (88.4 %) of the title product.

35

¹H NMR (CDCl_3): 2.24 ppm (s, 6H, $\text{N}(\text{CH}_3)_2$).


By means of the same process the hydrolysis of 6-O-desosaminyl-10-dihydro-10-deoxo-11-(n-propyl)-11-azaerythromycin A yielded the corresponding N-(n-propyl) derivative.

40

Claims

1. 10-dihydro-10-deoxo-11-azaerythronolide A compounds of the formula (IA)

45



50


55

60

65


wherein R₁ stands for a lower alkyl group, wherein the lower alkyl group comprises 1 to 3 carbon atoms, or a lower alkanoyl group, wherein the lower alkanoyl group comprises 1 to 3 carbon atoms, R₂, R₃ and R₄ have identical or different meanings and each stands for a hydrogen atom or a lower alkanoyl group, wherein the lower alkanoyl group comprises 1 to 3 carbon atoms, and their pharmaceutically acceptable acid addition salts.

5 2. A compound of formula (V)




wherein R₁ stands for a hydorgen atom, a lower alkyl group, wherein the lower alkyl group comprises 1 to 3 carbon atoms, or a lower alkanoyl group, wherein the lower alkanoyl group comprises 1 to 3 carbon atoms and R₂ stands for a desosaminyl group.

35 3. A method for the manufacture of 10-dihydro-10-deoxo-11-azaerythronolide A compounds of the formula (I)




60 wherein R₁ stands for a hydorgen atom, a lower alkyl group, wherein the lower alkyl group comprises 1 to 3 carbon atoms, or a lower alkanoyl group, wherein the lower alkanoyl group comprises 1 to 3 carbon atoms, R₂, R₃ and R₄ have identical or different meanings and each stands for a hydrogen atom or a lower alkanoyl group, wherein the lower alkanoyl group comprises 1 to 3 carbon atoms, and optionally pharmaceutically acceptable acid addition salts thereof, which comprises

A) a one- or two-step hydrolysis of 10-dihydro-10-deoxy-11-alkyl-11-azaerythromycin A of the formula (II)



wherein R₁ has the above meanings, R₂ stands for a desosaminyl group, R₃ stands for a cladinosyl group and R₄ stands for a hydrogen atom, or

B) the reaction of 10-dihydro-10-deoxy-11-azaerythronolide A of the formula (III)



with aliphatic aldehydes of the formula

R₅ - CHO (IV)

wherein R₅ stands for hydrogen or a lower alkyl group, wherein the lower alkyl group comprises 1 to 3 carbon atoms, in the presence of formic acid or hydrogen in the presence of a noble metal catalyst, and

C) optionally subjecting the products obtained according to A) or B) to acylation with lower aliphatic anhydrides, and optionally converting the products obtained according to A), B) or C) into pharmaceutically acceptable acid addition salts.


4. The use of compounds of the formula (I) in the manufacture of antiinflammatory active pharmaceuticals.

5. Antiinflammatory compositions comprising a pharmaceutically effective amount of a compound of the formula (I).

Patentansprüche

5

1. 10-Dihydro-10-deoxo-11-azaerythronolid-A-Verbindungen der Formel (IA)




30

worin R₁ für eine Niederalkylgruppe steht, worin die Niederalkylgruppe 1 bis 3 C-Atome umfaßt, oder eine Niederalkanoylgruppe, worin die Niederalkanoylgruppe 1 bis 3 C-Atome umfaßt, R₂, R₃ und R₄ dieselben oder unterschiedliche Bedeutungen haben und jeweils für ein H-Atom oder eine Niederalkanoylgruppe stehen, worin die Niederalkanoylgruppe 1 bis 3 C-Atome umfaßt, und ihre pharmazeutisch verträglichen Säureadditionssalze.

35

2. Verbindung der Formel (V)




60


worin R₁ für ein H-Atom, eine Niederalkylgruppe, wobei diese 1 bis 3 C-Atome umfaßt, oder eine Niederalkanoylgruppe steht, wobei diese 1 bis 3 C-Atome umfaßt, und R₂ für eine Desosaminylgruppe steht.

65

3. Verfahren zur Herstellung von 10-Dihydro-10-deoxo-11-azaerythronolid-A-Verbindungen der Formel (I)




- 25 worin R_1 für ein H-Atom, eine Niederalkylgruppe, worin die Niederalkylgruppe 1 bis 3 C-Atome umfaßt, oder eine Niederalkanoylgruppe steht, worin die Niederalkanoylgruppe 1 bis 3 C-Atome umfaßt, R_2 , R_3 und R_4 dieselben oder unterschiedliche Bedeutungen haben und jeweils für ein H-Atom oder eine Niederalkanoylgruppe stehen, worin die Niederalkanoylgruppe 1 bis 3 C-Atome umfaßt, und ihre pharmazeutisch verträglichen Säureadditionssalze, das
- 30 A) die ein- oder zweistufige Hydrolyse von 10-Dihydro-10-deoxo-11-alkyl-11-azaerythromycin A der Formel (II)



- worin R_1 die angeführten Bedeutungen hat, R_2 für eine Desosaminylgruppe steht, R_3 für eine Cladinosylgruppe steht und R_4 für ein H-Atom steht, oder
- B) die Umsetzung von 10-Dihydro-10-deoxo-11-azaerythronolid A der Formel (III)

60

65



mit aliphatischen Aldehyden der Formel

25


30 worin R₅ für Wasserstoff oder eine Niederalkylgruppe steht, wobei diese 1 bis 3 C-Atome umfaßt, in Anwesenheit von Ameisensäure oder Wasserstoff, an einem Edelmetallkatalysator und C) gegebenenfalls die Acylierung der nach A) und B) erhaltenen Produkte mit niederaliphatischen Anhydrienen und gegebenenfalls die Umwandlung der nach A), B) oder C) erhaltenen Produkte in pharmazeutisch verträgliche Säureadditionssalze umfaßt.

4. Verwendung der Verbindungen der Formel I zur Herstellung von entzündungshemmenden Arzneimitteln.

35 5. Entzündungshemmende Zusammensetzungen, die eine pharmazeutisch wirksame Menge einer Verbindung der Formel (I) aufweisen.


Re vendications

- 40 1. Composés de 10-dihydro-10-désoxo-11-azaérythronolidine A de formule (IA)




5 dans laquelle R₁ signifie un groupement alkyle inférieur, où le groupement alkyle inférieur comprend 1 à 3 atomes de carbone, ou un groupement alcanoyle inférieur, où le groupement alcanoyle inférieur comprend 1 à 3 atomes de carbone, R₂, R₃ et R₄ ont des significations identiques ou différentes et signifie chacun un atome d'hydrogène ou un groupement alcanoyle inférieur, où le groupement alcanoyle inférieur comprend 1 à 3 atomes de carbone, et leurs sels d'addition acides pharmaceutiquement acceptables.

2. Composé de formule (V)




dans laquelle R₁ signifie un atome d'hydrogène, un groupement alkyle inférieur, où le groupement alkyle inférieur comprend 1 à 3 atomes de carbone, où un groupement alcanoyle inférieur, où le groupement alcanoyle inférieur comprend 1 à 3 atomes de carbone, et R₂ signifie un groupement de désosaminyle.

3. Méthode pour la fabrication de composés de 10-dihydro-10-désoxy-11-azaérythronolidine A de formule (I)




60 dans laquelle R₁ signifie un atome d'hydrogène, un groupement alkyle inférieur, où le groupement alkyle inférieur comprend 1 à 3 atomes de carbone, ou un groupement alcanoyle inférieur, où le groupement alcanoyle inférieur comprend 1 à 3 atomes de carbone, R₂, R₃ et R₄ ont des significations identiques ou différentes et signifie chacun un atome d'hydrogène ou un groupement alcanoyle inférieur, où le groupement alcanoyle inférieur comprend 1 à 3 atomes de carbone, et facultativement leurs sels d'addition acides pharmaceutiquement acceptables, qui comprend

A) une hydrolyse en une ou deux étapes de 10-dihydro-10-desoxy-11-alkyl-11-azaérythromycine (A) de formule (II)



dans laquelle R₁ a les significations ci-dessus, R₂ signifie un groupement désosaminyle, R₃ signifie un groupement cladinosyle et R₄ signifie un atome d'hydrogène, ou

30 B) la réaction de 10-dihydro-10-désoxy-11-azaérythronolidine A de formule (III)



55 avec des aldéhydes aliphatiques de formule

R₅-CHO (IV)

60 dans laquelle R₅ signifie un atome d'hydrogène ou un groupement alkyle inférieur, où le groupement alkyle inférieur comprend 1 à 3 atomes de carbone, en présence d'acide formique ou d'hydrogène en présence d'un catalyseur de métal noble, et

C) facultativement soumettre les produits obtenus selon A) ou B) à une acylation avec des anhydrides aliphatiques inférieurs, et facultativement convertir les produits obtenus selon A), B) ou C) en sels d'addition acides pharmaceutiquement acceptables.

65

4. Utilisation de composés de formule (I) dans la fabrication de produits pharmaceutiques actifs comme anti-inflammatoires.

5. Compositions anti-inflammatoires comprenant une quantité efficace pharmaceutiquement d'un composé de la formule (I).

5

10

15

20

25

30

35

40

45


50

55

60

65

DIAGRAM 1

In vitro activity

IK = immuno complex

AZER = 10-dihydro-10-deoxy-11-methyl-11-azaerythronolide A (I)

DESAZ = 6-O-desosaminyl-10-dihydro-10-deoxy-11-methyl-11-azaerythromycin A (III)

DICL = diclofenac


D = D-penicillamine

A = lactate dehydrogenase

B = beta-glucurnidase

C = beta-N-acetyl glucosaminidase

DIAGRAM 2
In vitro activity



IK = immuno complex

DE = 10-dihydro-10-deoxo-11-azaerythronolide A

AE = 10-dihydro-10-deoxo-11-ethyl-11-azaerythronolide A

APR = 10-dihydro-10-deoxo-11-(n-propyl)-11-azaerythronolide A


ALA-3 = 4,6,13-O-triacetyl-10-dihydro-10-deoxo-11-azaerythronolide A

A = lactate dihydrogenase

B = beta-glucuronidase

C = beta-N-acetylglucosaminidase

DIAGRAM 3
In vivo activity



PCA = Freund's complete adjuvant

AZER = 10-dihydro-10-deoxy-11-methyl-11-azaerythronolide A (I)

DESAZ = 6-O-desosaminyl-10-dihydro-10-deoxy-11-methyl-11-azaerythromycin A (III)

DICL = diclofenac

D-PEN = D-penicillamine

A = lactate dehydrogenase

B = beta-glucuronidase

C = beta-N-acetyl glucosaminidase